http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020353007-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c16bf9485a5332aec59d5b282063ea25 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1382 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate | 2018-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b31e1eac10947c8f44577141bcc89401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d18e77c3f3db311c2a6dc9e00d78faa6 |
| publicationDate | 2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020353007-A1 |
| titleOfInvention | Pharmacological Composition for Prevention or Treatment of Lupus, Comprising Mesenchymal Stem Cell-Derived Secretome |
| abstract | The present disclosure relates to a composition for various applications, which is capable of effectively preventing, ameliorating or treating lupus using a secretome derived from mesenchymal stem cells. n The secretome derived from mesenchymal stem cells according to the present disclosure may significantly decrease mortality and the amount of proteinuria, and may increase body weight, decrease the expression of serum creatinine, and inhibit glomerular, coronary and vascular damage in kidney tissue. Furthermore, the secretome may reduce the size of an enlarged spleen and reduce the number of splenocytes and CD4-positive T cells. In addition, the secretome may increase the expression of the anti-inflammatory cytokines IL-10 and TGF-β1 in serum, and decrease the expression of anti-dsDNA antibody. In the mechanism thereof, the secretome may effectively prevent, ameliorate or treat lupus nephritis and, furthermore, lupus, by increasing the activity of Treg cells and inhibiting the activity of the inflammatory cells Th1 and Th2 cells, B cells, dendritic cells and inflammatory macrophages. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115851590-A |
| priorityDate | 2017-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 168.